Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.
about
Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolongWhat does an adult rheumatologist need to know about juvenile idiopathic arthritis?A commentary on TREAT: the trial of early aggressive drug therapy in juvenile idiopathic arthritis.2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening aPredictors of response to methotrexate in juvenile idiopathic arthritis.Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis.Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype.Methotrexate for treating juvenile idiopathic arthritis.Polyarticular juvenile idiopathic arthritis - epidemiology and management approachesA multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)Use of methotrexate in juvenile idiopathic arthritis.Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis.Current medical treatments for juvenile idiopathic arthritis.2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.Systemic arthritis in children: a review of clinical presentation and treatmentJuvenile spondyloarthritis treatment recommendationsA randomized placebo-controlled trial of methotrexate in psoriatic arthritisBlood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade.Vitamin D binding protein isoforms as candidate predictors of disease extension in childhood arthritis.Evaluation and Treatment of Childhood Enthesitis-Related Arthritis.Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome.Pain experience in children with juvenile idiopathic arthritis treated with anti-TNF agents compared to non-biologic standard treatment.Update on the treatment of juvenile idiopathic arthritisMethotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan.Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan.Challenges in the management of juvenile idiopathic arthritis with etanerceptEvaluation and Treatment of Enthesitis-Related Arthritis.Systemic JIA: new developments in the understanding of the pathophysiology and therapy.A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study.Treatment strategies for juvenile idiopathic arthritis.Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs.Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis.Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy.Update on the pathogenesis and treatment of systemic idiopathic arthritis.Defining juvenile idiopathic arthritis remission and optimum time for disease-modifying anti-rheumatic drug withdrawal: why we need a consensus.New advances in juvenile spondyloarthritis.Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis.Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives.Advances in the pathogenesis and treatment of systemic juvenile idiopathic arthritis.Treatment advances in systemic juvenile idiopathic arthritis.
P2860
Q24812856-4173D5A8-9F59-42D7-BED7-966DE8BE9586Q26995394-858AE767-B967-4961-AD10-E9E9B0BB6024Q31064321-870FD41A-1588-449F-8C19-1A105C601BC2Q33613293-2961F162-34CB-452C-B8DD-145E66D88C62Q34069374-20F0CC87-367A-4830-B656-CA734D07E213Q34196943-05C5DF42-23B4-4695-99EC-52F90D0543E9Q34235121-4D52DC72-A2D0-4172-9D9B-9C371C488644Q34424214-2037A29C-3D25-4315-B10D-9574556CD4A3Q34434750-C7EA935D-9F65-44C3-B1D3-57F4B7911D7FQ34758768-031C4AA5-A790-431D-9148-F5AC35962971Q35070936-BA5378AE-7672-4D6E-A3C0-8716AEBA0F39Q35082782-4E80139B-918D-4ECC-851C-01A7AC11C439Q35294398-B2627BDD-DCB6-4472-BA73-EBAA38B2F8B6Q35567870-02622C46-64AD-4D3A-9D3B-42F49E9FB3FEQ35659928-C30D4EDC-BC21-4504-B4C4-6AB7BC833E10Q36004879-6BA54BC8-1DE8-4F79-BEE3-40F5D9A25C74Q36096798-B81B3667-268B-4D79-90C4-8068A0301784Q36229664-D839FC7C-EF53-4809-8DCD-06A454B9DB3BQ36238059-4F164E09-8EEB-4C0C-9BEB-9A7AE27AAF6BQ36498631-B9C3A0F8-4D9A-494C-9DB0-992077B88D19Q36577397-F7EEAD3F-5C60-4038-B162-5896E6512C0BQ36843390-378CF1A8-7AAE-496B-B9D6-F696CF3AD8E5Q37060351-5BBF1C44-B051-4FC7-9A2C-02C009D08326Q37089689-F6575EF9-B2BD-46DD-905D-E10281222F85Q37235737-FE88CA83-DD9E-4299-96BA-8E9159FA389EQ37303219-78B51F4B-9F48-45C7-A567-763DCA1545B8Q37438552-723DC412-4A81-4400-A92C-2D233BC73FBAQ37620829-3C6C42D1-BEE1-49B5-A8FF-79B76BB8C23CQ37627929-1F2617A9-61F1-460E-8407-A5BD0C8B900EQ37642763-EF23D725-AFCA-4FA8-A072-62F9CFFBAF8EQ37775937-83BF2A28-7B5A-4EA5-B43B-33E80BD75E65Q37778738-6FDC9C68-BAB0-4A5C-9B52-34985660E028Q37866288-491C679C-CE82-43DF-93A2-DFC2F8AE7223Q37951816-299694E8-233F-4E60-A9A5-1EA438C5C38BQ37965666-86480895-4899-4415-B5B1-CEDDA4F7C0DBQ38001247-EB5A3651-A226-4BED-903C-C19389A9DBEEQ38087694-FC7E3132-2207-4125-9F33-F66FCC7F76CDQ38092899-73784979-F10E-47A5-8C66-8AB2D1FEC06DQ38161412-BCE5479A-2DAE-4350-9199-9DE48887E4F9Q38207061-587FAC1C-7EA2-485D-B4F3-725DF76F59C2
P2860
Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Randomized, placebo-controlled ...... ticular or systemic arthritis.
@ast
Randomized, placebo-controlled ...... ticular or systemic arthritis.
@en
type
label
Randomized, placebo-controlled ...... ticular or systemic arthritis.
@ast
Randomized, placebo-controlled ...... ticular or systemic arthritis.
@en
prefLabel
Randomized, placebo-controlled ...... ticular or systemic arthritis.
@ast
Randomized, placebo-controlled ...... ticular or systemic arthritis.
@en
P2093
P1476
Randomized, placebo-controlled ...... ticular or systemic arthritis.
@en
P2093
Grainger J
Southwood TR
P2860
P304
P356
10.1002/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F
P577
2000-08-01T00:00:00Z